Biotoscana Investments S.A. announced its results for the 4Q17 and full year of 2017.
MONTEVIDEO, Uruguay, March 19, 2018 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 4Q17 and full year of 2017.
HIGHLIGHTS
Gross revenues for 4Q17 grew 14% in constant currency, totaling BRL 271.6M.
Net revenues for 4Q17 increased by 17.8% in constant currency, totaling BRL 244.4M.
Gross profit up 14.4% in 4Q17, in constant currency, totaling BRL 140.3M. Gross margin of 57.4%.
Adjusted EBITDA grew 5.5% in constant currency vs. 4Q16, amounting to BRL 73.2M in 4Q17. 19.2% growth excluding from the base an insurance recovery decoupled from its underlying loss (in 2Q17)
Adjusted net income up 6.9% in nominal terms from 4Q16, reaching BRL 36.9M in 4Q17.
Net revenues for full year 2017 at 817.5M, with 14% organic growth (excluding exchange rate effects, short-term businesses, divestitures and acquisitions).
Adjusted EBITDA reached BRL 199.4M in 2017, up 23.9% in constant currency.
Gross margin for full year 2017 improved 3.8 pp when compared to 2016, reaching 53.8%. Adjusted EBITDA margin improved 2.5 pp, reaching 24.4%, in the same period.
